title: Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients.
abstract: OBJECTIVE
  The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon.
  
  
  RESULTS
  Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients.
  
  
  CONCLUSIONS
  HIV/HCV-coinfected patients, who, not too long ago, had inferior outcomes in capturing SVR, now enjoy similar fates as the monoinfected patients. They should thus be prioritized for treatment, since HCV and liver disease have become major causes of morbidity and mortality in this population. However, potential drug-drug interactions between antiretroviral agents and DAAs have to be systematically anticipated before initiating HCV therapy.
authors.affiliation: aInfectious Diseases Department, Mount Sinai Hospital, New York City, New York, USA bInfectious Diseases Department, University Hospital, Dijon, France cLiver Department, Mount Sinai Hospital, New York City, New York, USA.
authors.forename: David
authors.initials: D
authors.lastname: Del Bello
authors.forename: Fanny
authors.initials: F
authors.lastname: Ita Nagy
authors.forename: Jonathan
authors.initials: J
authors.lastname: Hand
authors.forename: Rabea
authors.initials: R
authors.lastname: Khedemi
authors.forename: Julien
authors.initials: J
authors.lastname: Lécluse-Barth
authors.forename: Douglas
authors.initials: D
authors.lastname: Dieterich
authors.forename: Lionel
authors.initials: L
authors.lastname: Piroth
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000379:methods; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents